CA2249390A1 - Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations - Google Patents

Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations

Info

Publication number
CA2249390A1
CA2249390A1 CA002249390A CA2249390A CA2249390A1 CA 2249390 A1 CA2249390 A1 CA 2249390A1 CA 002249390 A CA002249390 A CA 002249390A CA 2249390 A CA2249390 A CA 2249390A CA 2249390 A1 CA2249390 A1 CA 2249390A1
Authority
CA
Canada
Prior art keywords
melanoma
specific
cytotoxic lymphocytes
uses therefor
restricted cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002249390A
Other languages
English (en)
Other versions
CA2249390C (fr
Inventor
Craig L. Slingluff
Donald F. Hunt
Jeffrey Shabanowitz
Andrea L. Cox
Victor H. Engelhard
David Kittlesen
Jonathan Skipper
Ronald C. Hendrikson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Virginia Patent Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2249390A1 publication Critical patent/CA2249390A1/fr
Application granted granted Critical
Publication of CA2249390C publication Critical patent/CA2249390C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002249390A 1996-03-19 1997-03-17 Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations Expired - Fee Related CA2249390C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1397296P 1996-03-19 1996-03-19
US60/013,972 1996-03-19
US2762796P 1996-10-04 1996-10-04
US60/027,627 1996-10-04
PCT/US1997/004958 WO1997034613A1 (fr) 1996-03-19 1997-03-17 Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations

Publications (2)

Publication Number Publication Date
CA2249390A1 true CA2249390A1 (fr) 1997-09-25
CA2249390C CA2249390C (fr) 2007-12-18

Family

ID=26685490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002249390A Expired - Fee Related CA2249390C (fr) 1996-03-19 1997-03-17 Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations

Country Status (4)

Country Link
EP (1) EP0921805A4 (fr)
AU (1) AU712820B2 (fr)
CA (1) CA2249390C (fr)
WO (1) WO1997034613A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763071B1 (fr) * 1997-05-07 2003-05-16 Centre Nat Rech Scient Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
WO2000038515A1 (fr) * 1998-12-24 2000-07-06 New York Medical College Mimetiques peptidiques utiles pour traiter des maladies
AU2992600A (en) * 1999-02-11 2000-08-29 Genzyme Corporation Antigenic peptide concatomers
WO2001030847A1 (fr) 1999-10-22 2001-05-03 Aventis Pasteur Limited Molecule gp100 modifiee et ses applications
AU1440601A (en) * 1999-10-29 2001-05-14 Argonex Pharmaceuticals, Inc. Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
EP1355926A2 (fr) * 2000-05-31 2003-10-29 Genzyme Corporation Composes therapeutiques pour le cancer de l'ovaire
WO2002060390A2 (fr) * 2001-01-04 2002-08-08 Yale University Induction de reponses immunitaires a des antigenes modifies a l'isoaspartyle
DK1453471T3 (da) 2001-11-07 2011-03-28 Mannkind Corp Ekspressionsvektorer, der koder for epitoper af antigener, og fremgangsmåde til deres konstruktion
DE102005041616B4 (de) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
US8530182B2 (en) 2007-12-05 2013-09-10 Centers For Disease Control And Prevention Viral protein quantification process and vaccine quality control therewith

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0006916B1 (fr) * 1977-09-28 1981-07-08 National Research Development Corporation Préparations immunoligiques contenant MHC antigens et leur production
PT1025849E (pt) * 1992-12-22 2002-09-30 Ludwig Inst Cancer Res Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US6558671B1 (en) * 1997-01-30 2003-05-06 The University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor

Also Published As

Publication number Publication date
AU2424397A (en) 1997-10-10
EP0921805A4 (fr) 2002-06-26
AU712820B2 (en) 1999-11-18
EP0921805A1 (fr) 1999-06-16
CA2249390C (fr) 2007-12-18
WO1997034613A1 (fr) 1997-09-25

Similar Documents

Publication Publication Date Title
GB9626484D0 (en) Helicobacter pylori antigenic protein preparation and immunoassays
CA2118928A1 (fr) Conjugues saponine-antigene et leur utilisation
EP1564824A3 (fr) Composition de conversion d'énergie
AU1750097A (en) Highly concentrated, lyophilized, and liquid factor ix formulations
CA2267072A1 (fr) Anticorps anti-hm1.24 humain reconstitue
WO1996017072A3 (fr) Vecteurs d'alphavirus de recombinaison
EP0592202A3 (fr) D-ketohexose-3-épimerase, sa préparation et son utilisation.
FR2717550B1 (fr) Vanne cryogénique intégrale sous vide.
AU4556597A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
WO1995013297A3 (fr) Compositions immunogenes ameliorees agissant contre la gastrine humaine 17
CA2249390A1 (fr) Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations
AU9075591A (en) N-halochitosans, their preparation and uses
AU1218295A (en) Adjuvant for antigens, process for producing the same and its use
CA2042236A1 (fr) Epitopes ayant un effet seroreactif sur les proteines du papillomavirus humain (hpv) 18
CA2182889A1 (fr) Peptides reconnus par les lymphocytes cytotoxiques specifiques du melanome, et applications
AU662213B2 (en) Turbine and turbocharger using the same
EP0754229A1 (fr) L'alfamine, une proteine albuminoide serique humaine
AU1598500A (en) Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2
AUPO007396A0 (en) Ebv ctl epitopes
AU1086888A (en) Primary biliary cirrhosis autoantigen
AU6496094A (en) Tumor-associated antigens recognized by t cells and the uses of these antigens
WO1992017439A3 (fr) Diaminomesitylene perfluoroalkyle et polyimides obtenus avec celui-ci
AU2738088A (en) Soluble recombinant fce-receptor, the preparation and the use thereof
AU636907B2 (en) Bovine ephemeral fever and antigens and vaccines derived therefrom
AR244752A1 (es) Azocolorantes, procedimiento para su preparacion y su empleo.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed